A large body of evidence shows that 7 nicotinic acetylcholine receptor (nAChR) is an important mechanism underlying attentional and cognitive deficits in schizophrenia. Several compounds acting as activators of 7 nAChRs have been identified and investigated for a potential therapeutic application. However, considering the complexity of neuropsychiatric disorders and the difficulty to meet an ideal product profile for drug discovery in the field, there is the need to define empirical product profiles from available data for the major 7 activators. Two classes of compounds are described, partial/full 7 agonists and 7 positive allosteric modulators (PAMs). Their critical pharmacological features are analysed by focussing on type of activity/selectivity at 7 nAChR, action in vivo in laboratory animal models, desired clinical activity, pharmacokinetics (PK)/dosing and safety/tolerability issues. Although the characterization of type of efficacy in vitro succeeded in the extrapolation to animal models and to patients, more efforts are needed to improve selectivity, PK/dosing and safety/tolerability features for 7 agonists. Such as limitations have not been seen for 7 PAMs, so that this class may offer a potential back-up strategy for 7 activators development. The empirical profiles proposed here might give pragmatical indications for the development and the optimization of 7 activators. Few issues need to be further optimized, i), in the clinic, mostly PK profiling, and, ii), at a preclinical level, downstream 7 receptors mechanisms involved in cognitive deficits. A successfully translation of 7 activators research for the treatment of schizophrenic patients will rely on a continuous clinical/preclinical cross-talk approach.